Opinion

Video

Antibody-Drug Conjugates in Ovarian Cancer: Emerging Data and Treatment Integration

Author(s):

Angeles Alvarez Secord, MD, MHSc ,Dana M. Chase, MD, FACOG

Panelists discuss recent data on various antibody-drug conjugates (ADCs) in ovarian cancer, including mirvetuximab soravtansine from trials like FORWARD II, MIRASOL, and PICCOLO; luveltamab tazevibulin and rinatabart sesutecan from STRO-002-GM1 and REFRαME-O1; and raludotatug deruxtecan from REJOICE-Ovarian01, highlighting the evolving role of these agents in the treatment landscape for ovarian cancer.

Video content above is prompted by the following:

  • Briefly comment on recent data surrounding other antibody-drug conjugates in ovarian cancer and discuss the evolving role of these agents in the treatment landscape.
  • Mirvetuximab soravtansine (anti-FR) 
  • FORWARD II; MIRASOL; PICCOLO
  • Luveltamab tazevibulin (anti-FR), rinatabart sesutecan (Rina-S)
  • STRO-002-GM1; REFRαME-O1
  • Rina-S
  • Raludotatug deruxtecan (R-DXd, anti-CDH6)
  • REJOICE-Ovarian01 
Related Videos
2 KOLs are featured in this series.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment
September 15th 2021

Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment